First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Titel:
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Auteur:
Shi, Y.K. Wang, L. Han, B.H. Li, W. Yu, P. Liu, Y.P. Ding, C.M. Song, X. Ma, Z.Y. Ren, X.L. Feng, J.F. Zhang, H.L. Chen, G.Y. Han, X.H. Wu, N. Yao, C. Song, Y. Zhang, S.C. Song, W. Liu, X.Q. Zhao, S.J. Lin, Y.C. Ye, X.Q. Li, K. Shu, Y.Q. Ding, L.M. Tan, F.L. Sun, Y.